AlpaPICO: Extraction of PICO Frames from Clinical Trial Documents Using LLMs

In recent years, there has been a surge in the publication of clinical trial reports, making it challenging to conduct systematic reviews. Automatically extracting Population, Intervention, Comparator, and Outcome (PICO) from clinical trial studies can alleviate the traditionally time-consuming process of manually scrutinizing systematic reviews. Existing approaches of PICO frame extraction involves supervised approach that relies on the existence of manually annotated data points in the form of BIO label tagging. Recent approaches, such as In-Context Learning (ICL), which has been shown to be effective for a number of downstream NLP tasks, require the use of labeled examples. In this work, we adopt ICL strategy by employing the pretrained knowledge of Large Language Models (LLMs), gathered during the pretraining phase of an LLM, to automatically extract the PICO-related terminologies from clinical trial documents in unsupervised set up to bypass the availability of large number of annotated data instances. Additionally, to showcase the highest effectiveness of LLM in oracle scenario where large number of annotated samples are available, we adopt the instruction tuning strategy by employing Low Rank Adaptation (LORA) to conduct the training of gigantic model in low resource environment for the PICO frame extraction task. Our empirical results show that our proposed ICL-based framework produces comparable results on all the version of EBM-NLP datasets and the proposed instruction tuned version of our framework produces state-of-the-art results on all the different EBM-NLP datasets. Our project is available at \url{https://github.com/shrimonmuke0202/AlpaPICO.git}.

CrysAtom: Distributed Representation of Atoms for Crystal Property Prediction

Application of artificial intelligence (AI) has been ubiquitous in the growth of research in the areas of basic sciences. Frequent use of machine learning (ML) and deep learning (DL) based methodologies by researchers has resulted in significant advancements in the last decade. These techniques led to notable performance enhancements in different tasks such as protein structure prediction, drug-target binding affinity prediction, and molecular property prediction. In material science literature, it is well-known that crystalline materials exhibit topological structures. Such topological structures may be represented as graphs and utilization of graph neural network (GNN) based approaches could help encoding them into an augmented representation space. Primarily, such frameworks adopt supervised learning techniques targeted towards downstream property prediction tasks on the basis of electronic properties (formation energy, bandgap, total energy, etc.) and crystalline structures. Generally, such type of frameworks rely highly on the handcrafted atom feature representations along with the structural representations. In this paper, we propose an unsupervised framework namely, CrysAtom, using untagged crystal data to generate dense vector representation of atoms, which can be utilized in existing GNN-based property predictor models to accurately predict important properties of crystals. Empirical results show that our dense representation embeds chemical properties of atoms and enhance the performance of the baseline property predictor models significantly.

G4-Attention: Deep Learning Model with Attention for predicting DNA G-Quadruplexes

G-Quadruplexes are the four-stranded non-canonical nucleic acid secondary structures, formed by the stacking arrangement of the guanine tetramers. They are involved in a wide range of biological roles because of their exceptionally unique and distinct structural characteristics. After the completion of the human genome sequencing project, a lot of bioinformatic algorithms were introduced to predict the active G4s regions \textit{in vitro} based on the canonical G4 sequence elements, G-\textit{richness}, and G-\textit{skewness}, as well as the non-canonical sequence features. Recently, sequencing techniques like G4-seq and G4-ChIP-seq were developed to map the G4s \textit{in vitro}, and \textit{in vivo} respectively at a few hundred base resolution. Subsequently, several machine learning approaches were developed for predicting the G4 regions using the existing databases. However, their prediction models were simplistic, and the prediction accuracy was notably poor. In response, here, we propose a novel convolutional neural network with Bi-LSTM and attention layers, named G4-attention, to predict the G4 forming sequences with improved accuracy. G4-attention achieves high accuracy and attains state-of-the-art results in the G4 prediction task. Our model also predicts the G4 regions accurately in the highly class-imbalanced datasets. In addition, the developed model trained on the human genome dataset can be applied to any non-human genome DNA sequences to predict the G4 formation propensities.

Deep Graph Convolutional Network and LSTM based approach for predicting drug-target binding affinity

Development of new drugs is an expensive and time-consuming process. Due to the world-wide SARS-CoV-2 outbreak, it is essential that new drugs for SARS-CoV-2 are developed as soon as possible. Drug repurposing techniques can reduce the time span needed to develop new drugs by probing the list of existing FDA-approved drugs and their properties to reuse them for combating the new disease. We propose a novel architecture DeepGLSTM, which is a Graph Convolutional network and LSTM based method that predicts binding affinity values between the FDA-approved drugs and the viral proteins of SARS-CoV-2. Our proposed model has been trained on Davis, KIBA (Kinase Inhibitor Bioactivity), DTC (Drug Target Commons), Metz, ToxCast and STITCH datasets. We use our novel architecture to predict a Combined Score (calculated using Davis and KIBA score) of 2,304 FDA-approved drugs against 5 viral proteins. On the basis of the Combined Score, we prepare a list of the top-18 drugs with the highest binding affinity for 5 viral proteins present in SARS-CoV-2. Subsequently, this list may be used for the creation of new useful drugs.